JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE IMAGE: DR. GRAUPERA WITH THE MAIN RESEARCHERS OF THE PUBLICATION. LEFT TO RIGHT: ODENA VILALTA, LEONOR GOUVEIA, SANDRA CASTILLO, MARIONA GRAUPERA, HELENA SABATA, ANA ANGULO AND LAIA MUIXÍ. CREDIT: JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE Researchers from the Josep Carreras Leukaemia Research Institute find miransertib could reduce vascular malformations related to...
Tag: <span>therapy option</span>
Post
Study defines stem cell groups that drive myelodysplastic syndromes, finds potential targeted therapy option
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER Researchers from The University of Texas MD Anderson Cancer Center discovered that treatment resistance in patients with myelodysplastic syndromes (MDS) is caused by two distinct classes of stem cells and identified possible therapeutic approaches that target these cells. Their findings, which could have significant benefits for patients with disease...